Abstract Asthma has been demonstrated to be as common in the elderly as in younger age groups. Although no specific recommendations exist to manage the disease differently in older individuals, functional features and clinical presentations may be affected by age per se, and by age-related conditions, such as comorbidities and polypharmacy. In this review article, we aimed to explore the efficacy and safety in elderly asthmatic patients of one of the most currently used inhaled treatments for asthma, that is, the fixed-dose combination of budesonide/formoterol. We attempted to address some practical questions that are relevant to the daily practice of clinicians. We focused on the efficacy and real-world effectiveness of inhaled corticosteroids and long-acting badrenergic bronchodilators (ICS/LABA) as treatment in the elderly population, since data are extrapolated from younger populations. We investigated whether a maintenance and reliever therapy approach is more effective in the elderly as opposed to maintenance regimens, from both the general practitioner's and the pulmonologist's perspective. To address these questions, we scanned electronic databases (PubMed, MEDLINE, Embase, Scopus and Google Scholar) from the date of inception up to October 2016 with a crosssearch using the following keywords: 'asthma', 'elderly', 'SMART therapy', 'MART therapy', 'Turbuhaler', and 'budesonide/formoterol'. The available literature on the topic confirms that when the age-associated changes are properly managed in clinical practice, asthma in older populations can be optimally controlled with inhaled treatment including ICS/LABA. This also applies for the budesonide/formoterol fixed combination, thus allowing for the maintenance and reliever therapy approach.
Introduction
Asthma is a common chronic disease worldwide that affects children, adolescents and adults. Epidemiological studies [1] [2] [3] and daily clinical practice leave no doubt to the fact that asthma is as prevalent in the older ages as it is in the young. The question is whether asthma in the elderly maintains the same features of asthma in younger ages. Asthma in older ages is defined by distinctive characteristics due to the age-associated changes of the lung. Functional and immunological modifications associated with ageing affect the diagnostic approach and effective treatment in this group. In the current article, we address whether asthma in the most advanced ages poses a challenge with regards to current pharmacological treatment. In particular, we will explore in elderly asthmatics the efficacy (and effectiveness in real life), and safety of one of the most currently used inhaled treatments for asthma, the fixed-dose combination of an inhaled corticosteroid (ICS) and long-acting b-adrenergic bronchodilator (LABA). Specifically, we will focus on the combination of budesonide/formoterol, delivered by the Turbuhaler dry powder inhaler (DPI). We aim to answer some practical questions relevant to the day-to-day practice of clinicians. These questions are not meant to be hierarchical or all-inclusive, but in our view cover the major concerns practicing clinicians have related to the use of an ICS/LABA fixed-dose combination in elderly asthmatics.
The first question is whether (and to what extent) asthma in the elderly differs from that in younger ages. If so, how does it affect the overall management of the disease? The pharmacological treatment of elderly asthmatics should not only focus on the level of symptom control, but should also incorporate different domains such as comorbidities and polypharmacy, which are associated with high rates of adverse drug reactions in the elderly [4] . It must be stated that the knowledge of asthma in the elderly suffers from the fact that there has been very little original research in this field. This is because advanced age is invariably the exclusion criterion in almost all randomized clinical trials (RCTs), thus denying older asthmatic individuals access to experimental observations and interventional studies.
The second question focuses on the efficacy and effectiveness of ICS/LABA treatment in the elderly population, since data are extrapolated from observations in younger populations. A single inhaler containing ICS/LABA could potentially simplify the treatment regimen by improving adherence to therapy. The last decade has seen the establishment of ICS/LABA single-inhaler treatment being used as both maintenance and reliever therapy in asthma, without the need for additional short-acting b2-agonist (SABA) reliever therapy. The ease of the single-inhaler approach together with its simplicity is attractive to both clinicians and patients, which leads to the third question: could the 'flexible' approach be more effective in the elderly as opposed to maintenance regimens? The basis on which to decide which drugs to prescribe is an important aspect of caring for elderly people who need inhaled medications. This may be a difficult task both for general practitioners (GPs) and for pulmonologists. How do GPs and pulmonologists choose among different ICSs and LABAs?
The last question relates to the use of Turbuhaler DPI. Inhalers, which may seem easy to use to healthcare providers, frequently present challenges for elderly patients [5] . The combined effects of co-morbidities, the complexity of the accompanying medication regimen, as well as age-and disease-related lung function decline have a negative impact on cognitive abilities reducing the patients' capacity to concentrate on and take in complex instructions and information.
To address these questions, we scanned electronic databases (PubMed, MEDLINE, Embase, Scopus and Google Scholar) from the date of inception up to October 2016 with cross-search using the following keywords: 'asthma', 'elderly', 'SMART therapy', 'MART therapy', 'Turbuhaler', and 'budesonide/formoterol'. All studies considered to be relevant for these questions were evaluated with no restriction on study design and language of publication.
Is Asthma in Elderly Patients Different from Asthma in Younger Ages?
Most developed countries have accepted the chronological age of 65 years and older as a definition of 'elderly'. While this definition is somewhat arbitrary, it is usually associated with the age at which one can begin to receive pension benefits. The respiratory system undergoes structural changes with ageing that may lead to a functional condition that resembles that of airway obstruction [6] . The 'senile lung' presents with lung hyperinflation, which is a consequence of enlarged alveolar airspaces with no rupture of connective septa [7, 8] . It follows that the senile lung can be easily distinguished from the emphysematous lung by computed tomography lung density. The increased collapsibility of the airways with age [9] becomes evident at low lung volumes, leading to airflow limitation and airway closure. In addition to the structural alterations of the lung, ageing is associated with modifications of the immune system, which have been defined as 'immunosenescence'. The most important clinical consequence of immunosenescence is an increased susceptibility to viral or bacterial airway infections, which are responsible for the loss of asthma control [10] . Indeed, the age-associated changes of the immune system could account for the documented lower rates of atopy in elderly populations [11] . It is logical to hypothesize that, if functional and immunological conditions differ with age in asthmatic individuals, the clinical manifestations should also be different. A recent study reported that clinical features of asthma do not differ between very old ([80 years) and younger asthmatics [12] . However, subjects aged 80 years and over could represent a highly selected group of 'survivors', which limits the extrapolation to all older patients. The number of concomitant diseases increases with ageing [13] , and elderly asthmatics are therefore characterized by the concomitant occurrence of multiple pathological conditions. The number and the pattern of comorbidities in older asthmatics is higher than that encountered in younger subjects [14] . For example, depression is rare in young individuals, but very common in the elderly patient. Similarly, elderly asthmatics are also frequently affected by cognitive impairment. Both mood changes and cognitive deficit may have detrimental effects on asthma control [15] . Another important comorbid condition in elderly asthmatics is atrial fibrillation: an increased risk of new-onset atrial fibrillation has been demonstrated in asthmatics [16] . Comorbidities, which are the norm in older ages, carry the increased risk of polypharmacy and drug-drug interactions. Based on the above considerations, the management of asthma in the elderly should imply a more comprehensive approach and multidimensional treatment.
Is ICS/LABA Indicated in Elderly Asthmatics
as Well?
International guidelines on the management of asthma [17] do not specifically address treatment of disease in the advanced ages, and recommendations are extrapolated from studies conducted in younger subjects. Non-respiratory medications can interfere with respiratory drugs or with the disease itself [18] . This is the case with b-blockers, frequently prescribed in elderly subjects who suffer from cardiovascular diseases or administered as eye drops for glaucoma, where they can affect the lungs and facilitate bronchoconstriction [19] . In addition, asthmatics enrolled in RCTs are not fully representative of real-life patients [20] , and this is particularly true in elderly patients. The conclusion from the study of Battaglia and colleagues [20] is that almost half of elderly asthmatics are treated with drugs that have not been tested in such populations. Absorption, distribution, metabolism, and excretion of anti-asthmatic medications can be variably affected by agerelated decline in the function of the liver and the kidneys. Defects in the absorption may delay the time of onset of action of some drugs [21] . The risk for adverse drug reactions is augmented by the fact that renal failure is often unrecognized due to normal levels of serum creatinine. Reduced hepatic clearance of drugs increases the potential for drug interactions. The long-term and high-dose use of ICSs may be associated with increased risk of adverse events. Factors such as the patient's inhalation technique and peak inspiratory flow, which are variably impaired in elderly patients, can increase the occurrence of side effects. These include skin bruising, osteoporosis and bone fractures, cataracts, glaucoma, oral candidiasis, diabetes mellitus, and pneumonia. The pharmacokinetic and pharmacodynamics features of the ICSs are influenced by protein binding and bioactivation by first-pass metabolism of the liver. In their clinical practice, clinicians should be aware that the hepatic metabolism can be the cause of drug interactions.
Beta-2 adrenergic agonists, either SABAs or LABAs, bind to the b2-adrenoceptor, the response of which is different in elderly asthmatics due to increased sympathetic system activity, reduction in adenyl cyclase responses, and reduction in b2-adrenergic receptor numbers and affinity with ageing [22] . Anticholinergic drugs might represent a valid alternative to b2-agonists; however, their use in the elderly should take into consideration the potential risk of side effects, because of a decrease in the parasympathetic activity and reduction in receptor numbers or post-receptor coupling with aging [23] .
What is the Evidence in Support of the Maintenance and Reliever Therapy Approach Compared with Maintenance Treatment?
ICSs are considered the mainstay of treatment for patients with persistent asthma receiving a SABA. Those patients not adequately controlled on a low-dose ICS are steppedup in treatment with either the addition of a LABA, or an increase in the ICS dose [17] . The combination of low-dose ICS with LABA has been shown to achieve better asthma control than a higher dose of ICS [24] [25] [26] [27] [28] , with improved symptom control [24, 27] , better lung function [29] , a reduction in disease exacerbations [26] , and improvement in health status [25] . Evidence supports molecular interactions of the two drug classes that may underlie their complementary clinical benefit [30, 31] . Indeed, the availability of both drug classes in one inhaler device has been shown to be as safe and effective in achieving asthma control in the long-term treatment of asthma as two separate inhalers [32, 33] . A single-inhaler containing ICS/ LABA may simplify the treatment regimen by improving adherence to therapy and ensuring that the LABA is not administered as monotherapy without a concomitant antiinflammatory agent [34, 35] . Most recently, data show that in stable asthma patients who are adherent to their therapy, the use of a LABA together with an ICS in a single inhaler is safe [36] .
Adherence of patients with asthma to ICS therapy is poor [37, 38] ; possibly unsurprisingly as patients are asked to administer regular therapy irrespective of symptoms and naturally do not perceive tangible benefit from the ICS. There is over-reliance on SABA rescue use and also, conversely, under-use of preventer ICS therapy [39] . This has led to different therapeutic approaches in order to improve ICS adherence.
The traditional ICS/LABA therapeutic approach in asthma follows a fixed-dose maintenance regimen, where the patient administers the combination single-inhaler treatment at regular times in the day, with a separate SABA reliever inhaler on an as-needed basis, so many patients will be taking two different inhaler devices. A flexible, single-inhaler strategy can be considered for patients with inadequate asthma control and a frequent need for reliever medications, and asthma exacerbations in the past requiring medical intervention. Patients take a daily maintenance dose of ICS/LABA fixed combination and, in addition, use ICS/LABA fixed combination as-needed in response to symptoms. That is, the ICS/LABA combination single inhaler is used as both a preventer, with a regular twicedaily maintenance element of their treatment regimen, and also as a reliever. In clinical practice, a single administration of two consecutive inhalations of the ICS/LABA budesonide/formoterol combination as maintenance treatment is also permitted, thus allowing for a flexible treatment regimen that adapts to the needs of the patient.
The maintenance and reliever therapy approach results in an effective way of stepping up anti-inflammatory therapy in line with disease activity [40] . The rationale underpinning this approach is that at times of increased symptoms, the patient uses a higher dose of ICS in order to achieve disease control and reduce exacerbation risk. This allows for a degree of flexibility in ICS administration with the single-inhaler maintenance and reliever therapy approach, and a variable ICS dose to the patient that is higher when the patient has more symptoms, which might be more effective than a standard fixed-dose combination by increasing the dose only when needed and keeping it low during stable stages of the disease. Figure 1 summarizes the rationale and the potential of a flexible pharmacological approach to the asthmatic patient.
Most importantly, only those combinations that contain the rapid-onset acting LABA, formoterol (which is comparable to the onset of action of SABA) [41] , can currently be used with the maintenance and reliever therapy approach. Indeed, the Global Initiative for Asthma (GINA) document states at Steps 3-5 that low-dose ICS/formoterol can be used as reliever medication and maintenance therapy [17] . At present, four ICS/LABA combinations containing formoterol are specifically licensed in Europe to be used with the maintenance and reliever therapy approach in TM (budesonide/formoterol) is the most established in the so-called 'SMART' (Symbicort maintenance and reliever therapy) approach, where data show a reduction in the risk of severe exacerbations requiring oral corticosteroids, less hospitalizations, less ICS exposure without worsening of airway inflammation, and a reduction in non-adherence by patients to use of ICSs compared with higher doses of ICS alone or conventional fixed-dose ICS/LABA treatment with SABA as required [42] [43] [44] [45] [46] [47] [48] [49] . More limited but consistent data have been shown for Fostair Ò where patients receiving the socalled 'MART' (Maintenance and reliever therapy) approach significantly prolonged the time to first severe exacerbation and reduced the rate of severe exacerbations and oral corticosteroid courses compared with a standard fixed-dose beclometasone dipropionate/formoterol regimen and SABA as required [50] . Although there are no data specifically addressing these outcomes in the elderly, it is plausible to speculate that this is the case for older patients as well.
Earlier Cochrane reviews with the combination budesonide/formoterol (Symbicort TM ) as a SMART approach versus fixed-dose combination inhalers showed a reduction in exacerbations, but concluded the need for evidence of benefit over guideline-based treatment [51, 52] . A more recent Cochrane review concluded that combination budesonide/formoterol (Symbicort TM ) as a SMART approach versus fixed-dose combination inhalers reduces asthma exacerbations requiring oral corticosteroids and reduces emergency room admissions, with a lower mean daily ICS dose [53] . The single-inhaler SMART approach may be especially useful in those patients who have poor adherence to their regular preventer ICS treatment, where ICS use has been shown to increase in those receiving single-inhaler MART treatment [54] . Since older populations are at greater risk of poor adherence, they could greatly benefit from the SMART approach.
Certainly, the ease of the SMART approach and the comprehensive trial data supporting this approach, together with its simplicity, is attractive to both clinicians and patients. It is important that patients receive clear and adequate education on the flexible approach and the use of the single-inhaler concept. Importantly, it should be recommended to patients to have their inhaler at hand and available for rescue use at all times. An important signal to the clinician that a patient may not be managing this approach is the frequent use of rescue inhalations and patients should be prompted to return to their physician for reassessment. Concurrently, prescribers and pharmacists should monitor the number of prescriptions requested and any dose-related adverse effects.
How to Choose Among Different ICSs and LABAs? The GP Perspective in Real Life
''In my role as a General Practitioner, I was called to see a new patient in one of the old people's residential community homes we cared for. This man had memory problems and asthma which was poorly controlled; he had been taken to the ER department twice in the previous month for nebulized treatment for uncontrolled asthma. I discovered that every morning and evening, he was handed a beclomethasone pressurized Metered Dose Inhaler (pMDI) and told to take 2 puffs. From my observation, the man's inhaler technique was inadequate, and further complicated by the fact that he had osteoarthritis limiting his ability to actuate the device. I prescribed a large volume spacer and with help of those caring for the man we were able to improve his inhaler technique and asthma control.''
The number of critical errors in using inhaler devices increases with age [55] . In addition to increased prevalence of diseases such as COPD associated with ageing, older patients pose logistical challenges for prescribing physicians. In particular, these include patients' problems with manual dexterity, physical strength, hand-eye co-ordination, musculoskeletal problems, vision, hearing, as well as memory loss and dementia. While deciding which drugs to prescribe is an important aspect of caring for people with any illness, particular care needs to be taken in the case of inhaled medication. After deciding on the drug preparations, which have been dealt with in great detail elsewhere in this paper, it is essential to ensure that patients are taught technique, and that the chosen inhaler device can be used by the patient when prescribed. Clearly, hand-eye co-ordination and manual dexterity play a role in this process; however, other issues are just as important. These relate to the ability to follow instructions to prepare and load the device as well as being able to determine when it is empty and needs to be replaced with a new one.
There are tools available to assist patients who have problems with manual dexterity in inhaler use. These include, for example, the Handihaler by GlaxoSmithKline for use with pMDIs and the grip device provided by AstraZeneca for loading the Turbuhaler. While dose counters help users determine when devices are exhausted, older patients may not be able to see the counter because some of these are colored inappropriately (dark text on dark background) or the print is too small. Therefore, assessment of a patient's ability to read the counter is important in deciding which device to prescribe for a particular individual. Inhaler prescribing choices for patients with dementia can be informed by results of a Mini-Mental Test [56] . However, the ultimate test of a patient's ability to use an inhaler device is a demonstration of correct technique by the patient. In conclusion, when prescribing inhaled medication for older aged patients, it is important to consider their support structure, co-morbid conditions, and any factors that may limit the person's ability to remember to, or physically administer their medication, in addition to selecting the specific drugs indicated for the respiratory condition.
How to Choose Among Different ICSs and LABAs? The Pulmonologist Perspective in Real Life
Since ageing is associated with relevant anatomical and physiological changes [57] , the choice of ICS or LABA could be trivial in real life. Concerning b 2 -agonists, we should bear in mind that ageing is associated with an increase in sympathetic activity [58] . As a consequence, an alteration of the bronchodilator response to SABA and LABA has been suggested; moreover, an impairment of b 2 -receptor responsiveness has been observed [59] , while the number of b 2 -receptors seems similar in young and elderly people [60] , although contrasting results have been reported [61] . Experiences on LABA efficacy and safety in elderly are scanty. Sitar and colleagues showed that the optimal dose of formoterol does not change with age groups [62] ; nevertheless, it must be considered that in elderly individuals, the dose-dependent b 2 -agonists side effects such as the increase in myocardial oxygen consumption, increase in blood pressure, arrhythmias, and tremor can be increased [63] .
Although new LABAs (indacaterol, vilanterol, olodaterol) have been recently introduced in daily practice, formoterol and salmeterol still represent the benchmark. The relatively higher water solubility of formoterol and moderate lipophilicity ensure a more rapid access to the b 2 -receptors that can explain its faster onset of action than salmeterol [64] . Moreover, the different coupling/activation of b 2 -agonist receptor and/or signal transduction from this receptor is the cause of greater bronchodilatation when formoterol is combined with ICS [65] . Besides bronchodilatation, LABAs present other clinical effects such as increasing ciliary beat frequency [66] . The improvement of mucociliary clearance may be enhanced by the concomitant anti-inflammatory effect of ICS. The mucosal adsorption of ICSs is a function of their lipophilicity (higher for fluticasone propionate than for budesonide) [67] . Some anti-inflammatory effects have also been shown in vitro for LABAs, with a synergistic effect with ICSs [68] , and a protective effect against viral-induced inflammatory response [69] .
Despite sharing a similar basic mechanism of action, ICSs differ in terms of pharmacokinetic characteristics and therefore efficacy and safety. The binding affinity for the glucocorticosteroid receptor is particularly high for fluticasone and mometasone, and considered medium for budesonide; systemic bioavailability is limited for fluticasone, mometasone, and ciclesonide, is low for budesonide, whereas it is high for beclometasone and flunisolide; the volume of distribution is large for fluticasone and ciclesonide, intermediate for budesonide, mometasone, and beclometasone, and low for flunisolide; lung retention times are consistently lower for fluticasone than for budesonide [70] . When assessing fluticasone propionate and budesonide, the former persists longer in mucus, and more time is required for dissolving in the lining fluid, and for penetrating the airway wall. This may explain the high local anti-inflammatory activity and the long duration of action. On the other hand, the long duration of action of budesonide may result from different mechanisms such as active intracellular esterification and deposition. The more balanced lipophilic/hydrophilic characteristics of budesonide may explain its higher efficacy in terms of fast onset of action.
In asthma, budesonide/formoterol has been demonstrated to be as effective as fluticasone/salmeterol when administered regularly at equivalent daily doses [71] , while it was more effective than a fixed higher dose fluticasone/ salmeterol combination in improving lung function, quality of life, and in reducing the incidence of severe asthma exacerbations, hospitalization and emergency department visits, when used according to the maintenance and reliever strategy [42, 47] . With regard to safety, budesonide is associated with a lower risk of pneumonia [72] . Therefore, a comprehensive evaluation of the risk/benefit ratio should be made when deciding on the type of ICS/LABA combination, especially for elderly patients.
The DPIs for the Maintenance and Reliever
Therapy Approach: is Turbuhaler an Easy-toPerform Device for Elderly Patients?
In the traditional 'step-wise' asthma treatment approach, different classes of inhaled medications are added and doses increased when control is not achieved [17] . In clinical practice, most patients use two different inhaler types, more likely a DPI as a controller device and a pMDI as a reliever device [73] . However, such 'device mixing' (i.e., the prescription of more than one inhaler device type requiring different inhalation techniques for a single patient) could cause confusion for patients in the correct use of inhalers and, therefore, may have detrimental implications to patients' outcomes. Indeed, the use of mixed inhaler types for maintenance and reliever therapies is associated with higher rates of severe exacerbations and lower odds of achieving disease control in patients with asthma [74] . As discussed above, the risk of confusion is enhanced in elderly individuals who often suffer from cognitive impairment and mood changes, such as depression. The Turbuhaler was the first DPI to dispense doses metered from a reservoir inside the inhaler. The device has now been on the market for almost 30 years, during which it has undergone numerous design improvements. In the more recent formulation, the active agents are blended with lactose particles of similar size to that of the drug particles [75] . The particle blend is spheronized into small agglomerates, about 0.5 mm in diameter, which disintegrate into their primary particles during the inhalation process [75] . Extensive lung deposition studies have been carried out with the Turbuhaler device. In overview, about 35-40% of the drug dose reaches the lung at a flow rate of 60 L/min, whereas at 30 L/min the lung deposition is reduced and resembles that from a well used conventional pMDI [76] [77] [78] [79] . However, the lung deposition of budesonide delivered by Turbuhaler is at least twice that from a conventional pMDI [80] . This has led to recommendations to halve the dose when switching from conventional pMDI to Turbuhaler for the administration of budesonide.
A study of cognitively impaired patients aged 76-94 years who were instructed on inhaler use showed that, one day after training, 50% of patients with borderline cognitive impairment and virtually all patients with mild dementia do not operate pMDIs correctly [56] . Wieshammer and Dreyhaupt [81] , investigating handling errors with DPIs, found that the overall rate of ineffective inhalation was 31%, and the error rate increased with the increasing severity of the disease, and with no prior instruction in inhaler technique. In addition, besides the severity of disease, age critically determined the frequency of handling errors [82] . Thus, while the inhaler error rate was 20% for patients younger than 60 years of age, it doubled to 41.6% for those older than 60 years and even quadrupled to over 80% for those older than 80 years. Training by the healthcare provider more than halved the overall error rate from 53 to 23%, but in older patients, ineffective use of inhalers remained high despite prior instructions [82] .
Correct operation of a Turbuhaler involves at least five essential consecutive steps [83] . How feasible are these steps for older patients? Turbuhaler must be loaded in an upright position, at least 45°from the horizontal; once loaded, it may be used at any angle. A single dose is loaded when the grip at the base is fully twisted in one direction and back again. Inhalation through the mouthpiece forces air through the holes in the dosing disc, lifting the powder through the inhalation channel and into the de-aggregation zone consisting of two narrow spiral channels in the mouthpiece, which are aerodynamically designed to create a turbulent flow to disperse the powdered drug and provide respirable particles. Recent studies [83, 84] have shown that the use of DPIs that require few (3 or 4) essential steps to be correctly operated is associated with fewer critical errors in inhaler use than DPIs that need a higher number of operational steps for their correct usage. Common mistakes when using the Turbuhaler include failing to turn the base fully in both directions and failing to keep the device upright until loaded [83] . However, elderly patients appear to make fewer device-handling errors when using a DPI than with a pMDI [85] , even in combination with a large volume spacer [86] . Nevertheless, prescription of any inhaler device, including the Turbuhaler, for an elderly asthma patient should be preceded by a careful evaluation of the cognitive competency of the patient, as well as of his/her comorbidities. These constraints may be easily detected upon patient demonstration of each device.
The Spiromax (Teva Pharmaceutical Industries, Israel) and the Easyhaler (Orion Pharma, Finland) are generic DPIs delivering a budesonide/formoterol fixed-dose combination, licensed in Europe to be used with the flexible approach. The Spiromax is a novel multi-dose DPI designed to provide high-dose uniformity with maximum ease of use [87] . The devices delivers the drug using the new X-ACT technology, which comprises active metering and cyclone separator technology that breaks up the dry powder blend and separates fine drug particles from larger lactose particles [87] . The Easyhaler is a multidose DPI designed to resemble a conventional pMDI in terms of shape and operating principles, being both simple and practical [88] . Accurate dosing is achieved by pushing down the overcap of the device that rotates the metering cylinder at the bottom of the bulk chamber. The dose of drug to be inhaled is positioned in the mouthpiece, which is shaped to allow drug distribution to the airways.
Conclusions
The current article has attempted to answer some practical questions with regards to inhaled treatment with ICS/ LABA fixed combination delivered by the Turbuhaler device in the population of older asthmatics. Elderly chronic respiratory patients pose a challenge for physicians who must face a more complex, and sometimes complicated disease. This is mainly due to factors related to the individual (age-associated lung changes, complicating comorbidities, lack of adherence to treatment), the drug (age-related pharmacokinetic and pharmacodynamic changes), and the physician (low perception of the complexity of the disease and underestimation of the real prevalence of the disease in this age range). Overall, if the factors described in this article are properly taken into consideration in clinical practice, there is no reason not to believe that asthma can be fully controlled with inhaled treatment including ICS/LABA. This also applies for the budesonide/formoterol formulation, thus also allowing for the maintenance and reliever therapy approach. Finally, the use of the Turbuhaler device has been demonstrated to be well accepted by elderly asthmatics, providing support to the implementation of the SMART strategy in older populations.
